림프종

425개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved425 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTLimited DatastaleSecond Affiliated Hospital, Sch…Phase 1

CD70 CAR-NK (CD70 CAR-NK)

Relapsed/Refractory T-cell Lymphoma; Relapsed/Refractory Acute Myeloid Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleUTC Therapeutics Inc.Phase 2

CD70-targeting CAR-T cells (CD70-targeting CAR-T cells)

Lymphoma · Lymphoma

#Lymphoma#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleM.D. Anderson Cancer CenterPhase 2

CD70.CAR NK Cells (CD70.CAR NK Cells)

Large B-cell Lymphoma; Hodgkin Lymphoma · Large B-cell Lymphoma

#LargeB-cellLymphoma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleNantes University HospitalPreclinical

CEEP-RITUXIMAB (CEEP-RITUXIMAB)

Lymphoma, Large-Cell, Diffuse · Lymphoma, Large-Cell, Diffuse

#LymphomaLarge-CellDiffuse#Antibody#Preclinical#monoclonal-antibody#Lymphoma+3
Trials 1Status Active
CGTLimited DatastaleChi Kong LiPhase 2

CUCART19 (CUCART19)

Lymphoma, Nonhodgkin; Leukemia, Lymphocytic · Lymphoma, Nonhodgkin

#LymphomaNonhodgkin#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleThe First Affiliated Hospital o…Phase 1

CXCR4 CCR9 CAR-T (CXCR4 CCR9 CAR-T)

Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleCaribou Biosciences, Inc.Preclinical

Caribou-sponsored investigational therapy (Caribou-sponsored investigational therapy)

Lymphoma, Non-Hodgkin; Relapsed Non-Hodgkin Lymphoma · FRα

#FR#CGT#Preclinical#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited DatastaleMiltenyi Biotec, Inc.Phase 2

Chimeric Antigen Receptor (CAR, Chimeric Antigen Receptor, Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous))

B-Cell Lymphoma; B Acute Lymphoblastic Leukemia · B-Cell Lymphoma

#B-CellLymphoma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleJennifer Crombie, MDPhase 2

Chimeric Antigen Receptor (CAR, Chimeric Antigen Receptor, Chimeric Antigen Receptor (CAR) Therapy Infusion)

Primary Mediastinal Large B-cell Lymphoma (PMBCL); Primary Mediastinal Large B Cell Lymphoma · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleSouthwest Hospital, ChinaPhase 2

Chimeric Antigen Receptor Modified T cells Targeting CD19 (Chimeric Antigen Receptor Modified T cells Targeting CD19)

Leukemia; Lymphoma · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
AntibodyLimited DatastaleMedical College of WisconsinPhase 3

Cyclophosphamide and Rituximab (Cyclophosphamide and Rituximab)

Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma · Recurrent Grade 1 Follicular Lymphoma

#RecurrentGrade1FollicularLymphom#Antibody#Phase3#monoclonal-antibody#RecurrentGrade2FollicularLymphom+1
Trials 1Status Discontinued
AntibodyLimited DatastaleHeidelberg UniversityPhase 2

Cyclophosphamide, Pentostatin, Rituximab (Cyclophosphamide, Pentostatin, Rituximab)

Immunocytoma/Morbus Waldenström; B-Cell Non-Hodgkin's Lymphoma · Immunocytoma/Morbus Waldenström

#ImmunocytomaMorbusWaldenstrm#Antibody#Phase2#monoclonal-antibody#Immunocytoma+3
Trials 1Status Active
CGTLimited DatastaleBeijing GoBroad HospitalPhase 1

Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy (Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy)

B-cell Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleUniversity of Kansas Medical Ce…Phase 1

DuoCAR20.19.22-D95 (DuoCAR20.19.22-D95)

B-Cell Non-Hodgkin Lymphoma; B-cell Acute Lymphoblastic Leukemia · B-Cell Non-Hodgkin Lymphoma

#B-CellNon-HodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleRoswell Park Cancer InstitutePhase 1

EGFRt/19-28z/IL-12 CAR T-lymphocytes (EGFRt/19-28z/IL-12 CAR T-lymphocytes)

Recurrent Chronic Lymphocytic Leukemia; Recurrent Diffuse Large B-Cell Lymphoma · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleBeijing Boren HospitalPhase 1

Efficacy of LCAR-T2C CAR-T cells (Efficacy of LCAR-T2C CAR-T cells)

T Cell Lymphoma; T-cell Leukemia · T Cell Lymphoma

#TCellLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
AntibodyLimited DatastaleUniversity of Illinois at Chica…Phase 3

Elra (Elranatamab, Elranatamab (Elra))

Plasmablastic Lymphoma; Hiv · Plasmablastic Lymphoma

#PlasmablasticLymphoma#Antibody#Phase3#monoclonal-antibody#Hiv+1
Trials 1Status Recruiting
CGTLimited DatastaleBaylor College of MedicinePhase 1

Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells (Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells)

Non-Hodgkin Lymphoma; Chronic Lymphocytic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 3

Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix (Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix)

Primary Central Nervous System Lymphoma · Primary Central Nervous System Lymphoma

#PrimaryCentralNervousSystemLymph#Antibody#Phase3#monoclonal-antibody#Roche
Trials 1Status Recruiting
CGTLimited DatastaleBenjamin TomlinsonPhase 1

Fully human anti CD19 CAR-T Cell Dose (Fully human anti CD19 CAR-T Cell Dose)

Non Hodgkin Lymphoma; Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting

16 / 22 pages

← PreviousNext →